AdaptHealth (NASDAQ:AHCO) Price Target Lowered to $11.00 at UBS Group

AdaptHealth (NASDAQ:AHCO) had its target price cut by UBS Group from $12.00 to $11.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently weighed in on AHCO. Truist Financial decreased their price target on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Robert W. Baird decreased their target price on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada dropped their price target on AdaptHealth from $13.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group decreased their price objective on AdaptHealth from $14.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.20.

AdaptHealth Trading Down 0.2 %

Shares of AHCO opened at $8.93 on Thursday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -5.41, a PEG ratio of 1.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.24 and a quick ratio of 1.00. AdaptHealth has a 1-year low of $7.01 and a 1-year high of $11.90. The company has a 50-day moving average of $9.97 and a 200 day moving average of $10.29.

Institutional Trading of AdaptHealth

A number of hedge funds have recently bought and sold shares of the stock. Pacer Advisors Inc. purchased a new position in shares of AdaptHealth in the 4th quarter valued at $76,271,000. FMR LLC grew its stake in AdaptHealth by 9.3% in the third quarter. FMR LLC now owns 7,350,549 shares of the company’s stock valued at $82,547,000 after purchasing an additional 624,645 shares during the last quarter. Reinhart Partners LLC. raised its holdings in AdaptHealth by 1.1% in the fourth quarter. Reinhart Partners LLC. now owns 6,266,854 shares of the company’s stock worth $59,660,000 after purchasing an additional 68,212 shares in the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of AdaptHealth by 29.8% during the fourth quarter. Segall Bryant & Hamill LLC now owns 4,803,981 shares of the company’s stock valued at $45,734,000 after buying an additional 1,102,173 shares during the last quarter. Finally, State Street Corp lifted its position in shares of AdaptHealth by 19.8% during the third quarter. State Street Corp now owns 4,124,284 shares of the company’s stock valued at $46,316,000 after buying an additional 681,816 shares during the last quarter. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.